Given the well-established role of adipokines like leptin and adiponectin in MASLD development, we cannot exclude the possibility that either of these hormones was altered in the presence of NTS signaling. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.